Company: MIRM
Filing Date: 2025-08-06
Form Type: 10-Q
Source: 0001759425-25-000041
Chunk: 542

Company: Mirum Pharmaceuticals, Inc.
Filing Date: 2025-08-06
Form: 10-Q
Item: Part I, Item 2
Chunk 542
---
 of $1.3 million. 

Research and Development Expenses

The following table summarizes the period-over-period changes in research and development expenses relating to our product candidates in development for the periods indicated (in thousands):

Three Months Ended June 30,Change20252024Product-specific costs:Livmarli$3,321 $7,575 $(4,254)Volixibat12,550 7,842 4,708 MRM-33792,739 — 2,739 Non product-specific costs:Stock-based compensation7,624 3,546 4,078 Personnel14,604 8,460 6,144 Other5,229 5,249 (20)Total research and development expenses$46,067 $32,672 $13,395 

Research and development expenses were $46.1 million for the three months ended June 30, 2025, an increase of $13.4 million compared to the three months ended June 30, 2024. The increase was primarily due to:

•for volixibat programs, an increase of $4.7 million, primarily due to increased expenses associated with conduct of the PSC and PBC trials as well as manufacturing development expenses;

•for MRM-3379, an increase of $2.7 million, primarily due to planning for our Phase 2 study in Fragile X Syndrome and clinical manufacturing expenses;

•for personnel related and stock-based compensation expenses, an increase of $10.2 million related primarily to increased employee headcount and related equity award grants to support our development pipeline, partially offset by

•for Livmarli, a decrease of $4.3 million, primarily due to lower costs due to discontinuation of the biliary atresia clinical trial and other clinical costs partially offset by increased expenses associated with the Livmarli Phase 3 EXPAND label expansion study.

Selling, General and Administrative Expenses

Selling, general and administrative expenses were $63.3 million for the three months ended June 30, 2025, an increase of $14.1 million compared to the three months ended June 30, 2024. The increase was primarily due to increases of $8.9 million in personnel and other compensation-related expenses, including an increase of $2.6 million in stock-based compensation, reflecting an increase in the number of our selling, marketing and administrative employees to support commercial activities for our approved medicines,